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Introduction: Idiopathic pulmonary fibrosis (IPF) is a serious disease with unknown cause
and the influence of cytokine gene polymorphisms is presumed in the etiology and
pathogenesis of the disease. We used high-resolution computed tomography (HRCT) as a
marker of disease stage and progression and compared the alveolar and interstitial score
with IL-1, IL-4, IL-12, IL-1RA and IL-4RA cytokine gene polymorphisms.
Subjects and methods: The IPF patients were all Caucasians from the Czech Republic and
consisted of 20 females and 10 males, with a mean age of 65 years, range 36–85. The HRCT
results were evaluated by an experienced viewer using the interstitial and alveolar score
scales, which were based on the IPF HRCT description system from Gay SE, Kazerooni EA,
Tows GB, Lynch JP, Gross BH, Cascade PN, et al. [Idiopathic pulmonary fibrosis. Predicting
response to therapy and survival. Am J Respir Crit Care Med 1998;157:1063–72]. We
evaluated the polymorphisms of cytokine genes utilizing a PCR with sequence-specific
primers method.
Results: The HRCT alveolar score was more pronounced in IL-4 RA (+1902) AG
heterozygotes. The HRCT interstitial score was less severe in the IL-12 (1188) AA
homozygotes. According to progression of the HRCT interstitial score, the CC homozygosity
at IL-1 RA (mspa 111100), the AA homozygosity at IL-4 RA (+1902) and CC homozygosity atElsevier Ltd. All rights reserved.
1083728; fax: +420 241951417.
.cz (M. Vasakova).
ARTICLE IN PRESS
Cytokine gene polymorphisms and HRCT score in IPF 945IL-4(+33) positions were more frequent in patients with stable disease compared to those
with progressive disease.
Conclusions: We assume from our data that the polymorphisms of IL-4, IL-4RA, IL-1RA and
IL-12 genes (genes of cytokines with regulatory activity) might influence the phenotype of
IPF as shown by measurable changes in HRCT investigations.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is a serious disease
characterized by uncontrolled fibro-production as a seque-
lae of alveolar injury which devastates the lung architec-
ture.1–5 The etiology of the disease is still unknown, but an
impaired immunological response to some exogenous insult
in genetically disposed people is presumed.6–9
Previous studies have pointed out a correlation between
cytokine gene polymorphisms and IPF development. Whit-
tington et al.10 have studied the role of a novel IL-10 gene
polymorphism, a G to A substitution at position (+43) of the
start codon ensuing in lower levels of IL-10 protein
secretion. Studies of the effect of IL-13 on TGF-beta-1
activation implied that transgenic mice with over-expres-
sion of IL-13 are prone to generate airway and parenchymal
tissue fibrosis.11 Pantelidis et al.12 discovered an increased
frequency of the association of the IL-6 intron 4G and the
TNF-RII 1690C alleles in patients with IPF. The correlation of
the increased risk of fibrosing alveolitis associated with IL-1-
RA and TNF-alpha gene polymorphisms was previously
described.13 The potential role of TGF-beta 1 polymorphism
was also investigated. Polymorphisms in codons 10 and 25 of
the TGF-beta promoter do not predispose to the develop-
ment of IPF, while proline coded at codon 10 was associated
with an increase in alveolar arterial oxygen tension
difference during follow up.14 The TGF-beta 1 gene
polymorphism at the position (+915) of the signal sequence,
which changes codon 25 (arginine to proline) is associated
with inter-individual variation in levels of TGF-beta-1 and
that high production of TGF-beta 1 was present significantly
more frequently in patients with pretransplant lung fibrosis
and posttransplant allograft lung fibrosis.15 Studies of other
cytokine gene polymorphisms, which could influence the
susceptibility to IPF development are still continuing, with
often contradictory results.16,17 In our previous study, we
suspected a pathogenic role of IL-1, IL-2 and IL-4 cytokine
gene polymorphisms in IPF development.18
However, the influence of the gene polymorphisms alone
does not sufficiently elucidate the etiology and pathogenesis
of the disease. We suppose that the cytokine gene
polymorphisms would have been only the disease modifying
and predisposing factors and might influence the pronuncia-
tion of the pathogenic changes.
High-resolution computed tomography (HRCT) of the
lungs is one of the best, if not ultimately the best, method
for showing typical changes in IPF. Nevertheless, the
experience of the evaluating radiologist is an important
condition for the interpretation of accurate HRCT
changes.19,20 This fact is very important in case we cannot
obtain the biopsy specimen of lung tissue for histopatholo-gical verification of the diagnosis.21 The extent of reticula-
tion and honey-combing on HRCT is an important
independent predictor of mortality in patients with IPF.22
The inflammatory activity is supposed not to be the
dominant feature of the disease, but in some cases the role
of inflammatory changes is conceded and proved by Gallium-
67 citrate scans; nevertheless, it does not seem relevant for
the patient’s prognosis.23 The thin-section CT histograms of
the lungs were found to correlate well with results of
pulmonary function tests in IPF and therefore seem to be
suitable for use as valid indexes of IPF.24–26 Scoring systems
for the extent of the interstitial changes in IPF are used for
comparability of changes in time and between different
patients and also to make the results understandable
for other clinicians and radiologists. The scoring systems
have been designed by experienced pulmonary radiologists
and clinicians interested in IPF investigation.27–32 From
the pathologic point of view, the cystic lesions on HRCT
sections correlated well with micromorphology of the lung
tissue, but the pattern of activity (ground glass) and fibrosis
(consolidation) did not correlate with the histopathologic
findings.33
In our study, we have concentrated on the HRCT alveolar
and interstitial scores at the time of diagnosis and also their
dynamic changes in serial investigations and their correla-
tions with IL-1 alpha, IL-4, IL-12, IL-1RA and IL-4 RA gene
polymorphisms in patients with IPF.
The choice of the polymorphisms resulted from our
previous study of cytokine gene polymorphisms in IPF, where
the IL-1, and especially IL-4 polymorphisms seemed to be
strongly correlated with IPF presence compared to a healthy
population.18 The group of IL-1 cytokine gene polymorph-
isms in IPF showed some significant results also in the
previous study of Whyte et al. mentioned above.18 The IL-4
gene polymorphisms was to our knowledge investigated in
IPF patients only by our investigational group, and the
results encouraged us to correlate the findings with clinical
signs of the disease. The strongest correlation with IPF
development showed the IL-4 polymorphism at position
(33), where the prevailing genotype in the IPF group was
compared by CT to the healthy controls with CC (Po0.0001)
and the P-value remained statistically significant even after
a Bonferroni correction (Pcorro0.0022).18 The IL-12 gene
polymorphisms were involved in our study according to
regulatory function of this cytokine in immune reactions,
despite the fact we did not prove in our previous study the
significant correlation with IPF development.18 The pivotal
idea of the choice of cytokine polymorphisms was the
hypothesis of the prevalence of Th2 type of immune
response in IPF leading to extensive fibrosis as an answer
to multiple insults of alveolar wall.
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Study subjects and study design
The IPF patients were all Caucasians from the Czech
Republic and consisted of 20 females and 10 males, with a
mean age of 65 years, range 36–85. All the patients with IPF
were diagnosed according to American Thoracic SocietyTable 1 HRCT scoring system in IPF (based on scoring
system of Gay et al.).
Alveolar score Interstitial score
0 0 0, no honey-combing
1 1–4% 1–4%, no honey-combing
2 4–24% 5–24%
3 25–49% 25–49%
4 50–74% 50–74%
5 75%–100% 75–100%
Table 2 HRCT score in IPF patients.
IS I IS II IS III IS IV AS I A
13. 2 4 2 2
2. 3 3 4 4 4 3
23. 4 4 2
5. 3 4
57. 3 3
44. 4 3 3 1
60. 4 4 3 1
8. 4 4 1 2
18. 3 5 5 4
35. 3 2
54. 3 3
21. 4 3
62. 5 3
6. 5 5 3 3
32. 3 1
2. 4 4 4 4 0 3
49. 4 0
3. 3 4 2
31. 4 4 4 2
33. 4 1
38. 4 2
47. 3 3 1 1
11. 4 4 4,5 4 3 2
43. 3 4 4 1 1
37. 5 5
55. 5 0
20. 4 4 5 4 4
IS ¼ interstitial score.
AS ¼ alveolar score.
Dynamics: 0—without changes, 1—regression, 2—progression.
I—at the time of diagnosis.
II—1–11 months after diagnosis.
III—12–23 months after diagnosis.
IV—24–36 months after diagnosis.(ATS)/ European Respiratory Society (ERS) consensus classi-
fication34 and all signed an informed consent form. The
study was approved by Central Ethical Committee of
University Thomayer Hospital and Institute for Clinical and
Experimental Medicine.
After the basal demographic data such as race, age and
sex was collected, the HRCT of the lungs was performed at
the time of the diagnosis and then repeated every 12 months
(Tables 1 and 2). Polymorphisms in the promoter regions of
the IL-1alpha, IL-4 and IL-12 and translated regions of IL-4RA
and IL-1RA genes were characterized. The cytokine gene
polymorphisms were chosen on the basis of our previous
study18 (Table 3). The results were then statistically
evaluated.
The HRCT investigation was performed on the SOMATOM
Sensation 40 machine (Siemens AG, Berlin and Munich,
Germany). The results were evaluated by an experienced
viewer using the interstitial and alveolar score scales, which
were based on the IPF HRCT description system of Gay
et al.29 (Tables 1 and 2). The HRCT scores were evaluated at
four levels: aortic arch, hilar level, right atrium and basal
parts of lungs. The values are stated in percentages andS II AS III AS IV Dynam. IS Dynam. AS
2 0
1 2 2 1
1 0 1
2 2
0 1
0 2
4 2 1
0 0
2 1 0 1
3 2 2
0 1
0 0
3 2 2 1
1 2 0
4 2 0
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Table 3 List of investigated cytokine gene polymorph-
isms.
Polymorphism Genotypes
IL-1alpha 889 C/C C/T T/T
IL-4 11098 G/G G/T T/T
IL-4 590 C/C C/T T/T
IL-4 33 C/C C/T T/T
IL-4RA +1902 A/A A/G G/G
IL-12 1188 A/A A/C C/C
IL-1 RA mspa111100 C/C C/T T/T
Table 4 Correlation of the HRCT alveolar score at the
time of diagnosis and IL-4 RA (+1902) polymorphisms.
AS 0+1 groups AS 2+3 groups AS 4+5 groups
AA 5 (31%) 10 (63%) 1 (6%)
AG 3 (27%) 3 (27%) 5 (46%)
Po 0.05.
Table 5 Correlation of the HRCT interstitial score at
the time of diagnosis and IL-12(1188) polymorphisms.
IS 2+3 groups IS 4+5 groups
AA 10 (55,5%) 8 (44,5%)
AC, CC 1 (11%) 8 (89%)
Po0.05.
Table 6 Correlation of the HRCT interstitial score
changes and IL-1RA (mspa 111100) polymorphisms.
Stable disease Progressive disease
CC 6 (75%) 2 (25%)
CT 0 4 (100%)
TT 2 (67%) 1 (33%)
Po0.05.
Cytokine gene polymorphisms and HRCT score in IPF 947describe the extent of changes. We considered the disease
to be stable for value 0 and 1 and to be progressive, for
value 2 in columns showing the score changes in Table 3.
DNA extraction from the peripheral blood sample
Ten millilitres of venous peripheral blood was collected in
EDTA tubes and a red cell lysis buffer was added. After
20min, the tube was spun for 10min at 1300g and the
supernatant was removed. White cell lysis buffer was then
added to the sediment with proteinase and SDS. The mixture
was incubated on a rotator for 18 h at 37 1C. After the
incubation, 6M NaCl and chloroform was added and mixed
for 15 s before being centrifuged for 25min at 1300g.
The supernatant was added to 4ml of absolute ethanol in
a clean tube. The precipitated DNA was removed, resus-
pended in sterile water and stored at 4 1C.
Cytokine genotyping
We evaluated the polymorphisms of cytokine genes utilizing
a cytokine genotyping kit (Dynal Biotech, Oslo, Norway). The
test is designed as a PCR with sequence-specific primers.
The whole procedure was performed according to the
manufacture’s instructions. The preparation of PCR master
mix consists of 140 5 l PCR Buffer, 75 5 l genomic DNA
(75–120 ng/5 l), 4 5 l Taq polymerase (5U/5 l) and 261 5 l PCR
H2O. Ten 5 l of this mixture is then dispensed to each well of
the tray. The thermal cycling programme for PTC 225 DNA
Engine Tetrad (MJ Research, USA) was as follows: initial
denaturation 94 1C for 2min, then 10 cycles of 94 1C 15 s and
65 1C 60 s, and then 20 cycles of 94 1C 15 s, 61 1C 50 s and
72 1C 30 s.
After the cycling is completed, the PCR products are
loaded onto a 2% agarose gel stained with ethidium bromide
for electrophoresis (5 V/cm). The obtained pattern of
positive and negative PCR is documented and interpreted
according to the manufacturer’s instructions.
Statistical analysis
Descriptive statistics were calculated (i.e. mean value and
standard deviation) and derived from the quantitative
variables. For discrete variables (genotype, etc.) the chi-
square, resp. Fisher’s exact test was used. A multiway
frequency table was used for the evaluation of an associa-
tion between the polymorphisms in the group of patients.Results
The highest HRCT alveolar score (4+5) was associated with
IL-4 RA (+1902) AG heterozygotes as compared with AA
homozygotes (Table 4). When we compared the results with
the results of our group of 103 healthy volunteers from the
previous study, the AA homozygosity at this position seemed
to appear at a similar percentage in IPF patients with
alveolar score 2+3 and in the healthy volunteers (63% vs.
55%).18
The HRCT interstitial score was less severe in the IL-12
(1188) AA homozygotes (Table 5). When we looked at the
healthy population, the prevailing genotype is also AA at this
position (55%), AC and CC is present in 41% of our healthy
volunteers compared to 89% seen in IPF patients with
interstitial score 4+5.18
According to the progression of the HRCT interstitial
score, the CC homozygosity at IL-1 RA (mspa 111100), the AA
homozygosity at IL-4 RA (+1902) and CC homozygosity at IL-
4(33) were more frequent in patients with stable disease
compared to that with progressive disease (Tables 6–8). We
are aware that the subgroups of patients in these groups are
limited, but when comparing the frequency of the IL-4(33)
CC polymorphism in the healthy population vs. IPF patients
it can be seen that 75% of the healthy subjects in our control
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Table 7 Correlation of HRCT interstitial score changes
and IL-4RA (+1902) polymorphisms.
Stable disease Progressive disease
AA 8 (67%) 4 (33%)
AG 0 3 (100%)
Po0.08.
Table 8 Correlation of HRCT interstitial score changes
and IL-4 (33) polymorphisms.
Stable disease Progressive disease
CC 4 (100%) 0
CT 4 (36%) 7 (64%)
Po0.08.
M. Vasakova et al.948group are CC homozygotes, compared to 0% of the IPF
patients with progressive disease.18 In the case of IL-1RA
(mspa 111100) and IL-4 RA (+1902) polymorphisms, compar-
ison with the previous results of the healthy population
showed no reasonable explanation for any allele carriage
and IPF progression.
The other polymorphisms did not show a statistically
significant correlation with HRCT markers of IPF either at
the diagnosis or during follow up.
No association between the polymorphisms in IPF patients
was found using multiway contingency tables.Discussion
In order to investigate the influence of our previously
investigated polymorphisms on the IPF manifestation, we
chose the HRCT of the lungs as the best measurable and
easiest to evaluate marker of the disease.22,24–30,32 We
compared the alveolar and interstitial score and its
progression in time with cytokine gene polymorphisms at
the (889) IL-1 alpha, (1098) IL-4, (590) IL-4, (33) IL-4,
(+1902) IL-4RA, (mspa 111100) IL-1RA and (1188) IL-12
positions.
In our previous study,18 we investigated a wide spectrum
of cytokine genes with special attention paid to IL-4 and
found statistically significant results for IL-4 polymorphisms
at positions (590) (CT) and (33) (CT) in IPF patients.
These results support the idea of the pathogenic role of the
IL-4 promotor polymorphisms in IPF and are in agreement
with the work of Jakubzick et al., describing the influence of
IL-4 on lung cells, especially in fibroblasts.35 However, the
functional consequences of the described IL-4 polymorph-
isms, i.e. whether these polymorphisms influence the
amount of produced IL-4, or induce changes in its affinity
to the IL-4 receptors on lung fibroblasts, are not known.
We found that the higher alveolar score, i.e. a greater
extent of active changes at the time of diagnosis, in IL-4RA(+1902) AG heterozygotes. The lower interstitial score, i.e.
the less extent of the fibrotic chages, was found in the IL-12
(1188) AA homozygotes compared to AC heterozygotes.
According to the progression of the disease in serial HRCT
investigations, the CC IL-1RA (mspa 111100) homozygotes
had a lower grade of progression of the interstitial score
(i.e. fibrosis) than the CT heterozygotes and TT homozy-
gotes. Similarly, the IL-4RA (+1902) AA homozygotes had
lower progression of the interstitial score than the AG
heterozygotes and CC IL-4 (33) homozygotes had lower
interstitial score progression than the CT heterozygotes at
this position.
We found most promising the results which showed a
reasonable correlation with results previously seen in our
healthy volunteer group.18 I.e. the ones where a carriage of
some allele was different or similar in frequency in healthy
vs. IPF patients and prone their carrier to have more or less
severe HRCT score. Such correlations were seen for IL-
4RA(+1902) AA homozygosity seen in similar fashion in IPF
patients with a higher alveolar score and in healthy patients.
IL-12 is a key regulator of the polarisation of immune
responses to T helper 1 or 2 pathways and plays a role in
autoimmune and infectious diseases.36 Nevertheless, Latsi
in his study did not find any association with susceptibility to
IPF and neither did we in our previous work.18,37 According
to the IL-12(1188) polymorphisms in our study, the most
frequent one in the group of healthy volunteers is AA and
these homozygotes in IPF group had a lesser extent of
interstitial changes, e.g. a more favourable outcome
compared to the homozygous or heterozygous carriers of
allele G, who had the worst interstitial score 4+5.
The genotype preserving IPF patients in our group from
rapid progression of interstitial changes was IL-4(33) CC
homozygosity, which appeared also in majority of healthy
subjects in our control group (75%) and in none of the
patients with rapid progression.18
IL-1 alpha 889 did not seem to be correlated either with
the interstitial and alveolar score at the time of diagnosis or
with changes in the score during follow-up. But the
other cytokine polymorphism from IL-1 group, the investi-
gated IL-RA mspa 111100 polymorphism, showed greater
probability of having a stable disease without progression
of the interstitial score for CC homozygotes. This homo-
zygosity is the least frequent genotype in heatlhy population
which makes the function of this polymorphism in IPF
unclear.
We are aware that the number of patients in our study
group is not large enough to generate the results with
greater statistical significance, but we suppose from our
results that the polymorphisms of IL-4, IL-4RA, IL-1RA and IL-
12 genes (genes of cytokines with regulatory activity) could
influence the phenotype of the idiopathic pulmonary fibrosis
shown as measurable changes in HRCT investigations. Our
next goal is to enlarge the IPF group to obtain greater
statistical sensitivity and to test the functional relevance of
the polymorphisms in IPF with help of gene expression of
cytokines m-RNA i bronchoalveolar lavage fluid.
We are aware that cytokine gene polymoprhisms are
obviously not the only factor influencing the IPF develop-
ment and progression and could be a result of the synergic
effect of manifestation of variation of cytokine genes and
imbalance in tissue remodelling mediators.38
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